Compare Inovio Pharmaceuticals Inc (INO) vs NetEase Inc (NTES) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs NetEase Inc — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while NetEase Inc trades at $131.06 (market cap $86.14B). The key difference: NetEase Inc is far larger — about 964.9× Inovio Pharmaceuticals Inc's market cap, and NetEase Inc pays a 2.25% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | NTES | |
|---|---|---|
Market Cap | $89.27M | $86.14B |
Sector | Health | Media |
52-Week High | $2.87 | $159.34 |
52-Week Low | $1.05 | $109.26 |
Enterprise Value | $60.28M | $62.61B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
NetEase (NTES) trades at $134.20, up 2.22% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.53, and maintains robust profitability with a net income margin near 30%. Recent news highlights international expansion and positive analyst sentiment, with a dividend of $0.72 paid in June 2026.
Outlook remains positive driven by earnings growth and international gaming titles, but risks include China market volatility and competitive pressures. Wall Street consensus is strongly bullish with 82% buy ratings, suggesting potential upside from current levels amid solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →
